iBio Faces NYSE American Delisting Risk

Ticker: IBIO · Form: 8-K · Filed: 2025-02-19T00:00:00.000Z

Sentiment: bearish

Topics: delisting, compliance, stock-exchange

Related Tickers: IBIO

TL;DR

NYSE American might delist iBio, Inc. - big trouble ahead.

AI Summary

On February 19, 2025, iBio, Inc. filed an 8-K to report its notice of delisting or failure to satisfy continued listing rules. The company is facing potential delisting from the NYSE American, indicating a significant financial or operational challenge.

Why It Matters

This filing signals potential severe financial distress for iBio, Inc., which could lead to its stock being removed from a major exchange, impacting investor confidence and liquidity.

Risk Assessment

Risk Level: high — The company has received a notice of delisting or failure to satisfy continued listing rules, indicating a severe risk to its stock market presence.

Key Players & Entities

FAQ

What specific continued listing rule has iBio, Inc. failed to satisfy?

The filing states that iBio, Inc. received a notice of delisting or failure to satisfy a continued listing rule or standard, but the specific rule is not detailed in this 8-K filing.

What is the potential consequence of failing to satisfy the listing rule?

The potential consequence is delisting from the NYSE American, meaning the company's stock would no longer be traded on that exchange.

Has iBio, Inc. been given a specific timeframe to regain compliance?

This 8-K filing does not specify a timeframe for iBio, Inc. to regain compliance with the listing standards.

What actions, if any, does iBio, Inc. plan to take in response to the notice?

The filing does not detail any specific actions iBio, Inc. plans to take in response to the delisting notice.

When was this notice of delisting received by iBio, Inc.?

The 8-K filing was made on February 19, 2025, reporting the notice of delisting or failure to satisfy continued listing rules.

From the Filing

0001420720-25-000014.txt : 20250219 0001420720-25-000014.hdr.sgml : 20250219 20250219162531 ACCESSION NUMBER: 0001420720-25-000014 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20250219 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250219 DATE AS OF CHANGE: 20250219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 25640525 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 ibio-20250219x8k.htm 8-K iBio, Inc._February 19, 2025 0001420720 false 0001420720 2025-02-19 2025-02-19 ​ ​ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM  8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 19, 2025 iBio, Inc. (Exact name of registrant as specified in charter) Delaware (State or other jurisdiction of incorporation) ​ ​ 001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.) ​ 11750 Sorrento Valley Road, Suite 200 San Diego, California 92121 (Address of principal executive offices and zip code) ( 979 ) 446-0027 (Registrant’s telephone number including area code) N/A (Former Name and Former Address) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions: ☐       Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐       Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12) ☐       Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐       Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: ​ ​ ​ Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock , $0.001 par value per share IBIO NYSE American ​ Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company   ☐ If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨ ​ ​ ​ ​ Item 3.01.   Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On February 19, 2025, iBio, Inc., a Delaware corporation (the “Company”), acting pursuant to authorization from its Board of Directors (the “Board”), determined to voluntarily withdraw the listing of the Compan

View on Read The Filing